Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental combo shows promise in Tough-to-Treat lung cancer

NCT ID NCT02823990

First seen Nov 10, 2025 · Last updated May 22, 2026 · Updated 26 times

Summary

This study tested a new combination treatment for people with advanced non-small cell lung cancer that had already been treated. The treatment combined a cancer vaccine (TG4010) with an immunotherapy drug (nivolumab) to help the immune system fight the cancer. The trial included 13 patients and aimed to see if the combination could shrink tumors or stop them from growing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT NON-SMALL CELL LUNG CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • UCSF Medical Center-Mount Zion

    San Francisco, California, 94115, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States

  • University of California San Diego

    San Diego, California, 92103, United States

Conditions

Explore the condition pages connected to this study.